Currently, there are 853.39M common shares owned by the public and among those 91.82M shares have been available to trade.
The company’s stock has a 5-day price change of 18.64% and -16.42% over the past three months. IBRX shares are trading 9.38% year to date (YTD), with the 12-month market performance down to -65.43% lower. It has a 12-month low price of $1.83 and touched a high of $8.07 over the same period. IBRX has an average intraday trading volume of 7.75 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 13.89%, 5.16%, and -19.90% respectively.
Institutional ownership of ImmunityBio Inc (NASDAQ: IBRX) shares accounts for 9.21% of the company’s 853.39M shares outstanding.
It has a market capitalization of $2.47B and a beta (3y monthly) value of 0.06. The earnings-per-share (ttm) stands at -$0.58. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.87% over the week and 8.95% over the month.
Earnings per share for the fiscal year are expected to increase by 26.43%, and 41.25% over the next financial year.
Looking at the support for the IBRX, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on March 06, 2025, with the firm’s price target at $8. BTIG Research coverage for the ImmunityBio Inc (IBRX) stock in a research note released on January 10, 2025 offered a Buy rating with a price target of $6. Piper Sandler was of a view on May 12, 2023 that the stock is Neutral, while Jefferies gave the stock Buy rating on August 03, 2022, issuing a price target of $8.
